New research from the Los Angeles Biomedical Research Institute (LA BioMed) found a progestogen-only treatment halted bleeding in women suffering from extremely heavy periods,
according to the study published online by the American Journal of Obstetrics and Gynecology.
"Excessive uterine bleeding is a common problem we see in gynecological practices and emergency rooms. It can interfere with women's daily activities and put them at risk for anemia and other more serious health consequences caused by blood loss," said Anita L. Nelson, MD, a LA BioMed lead investigator and corresponding author of the study. "Until now, there has been no Food and Drug Administration-approved products for short-term treatment of this condition. Based on our study, we conclude that this new progestogen-only treatment is effective in stopping acute abnormal uterine bleeding."
Within five days of receiving the therapy, bleeding had ceased in 44 of the 48 women in the study, and the other four were only experiencing spotting. The mean time to bleeding cessation was 2.6 days, leading the researchers to conclude the progestogen-only treatment was an effective short-term therapy for acute abnormal uterine bleeding.
In the pilot study, the patients received a 150-milligram injection of Depomedroxyprogesterone acetate (DMPA) and then were given medroxyprogesterone acetate (MPA) 20 milligram pills that were to be taken orally every eight hours for three days.
"This is the largest prospective study to date to measure the effectiveness of a proposed hormonal treatment for excessive uterine bleeding," said Dr. Nelson. "The women in the study experienced excellent success with this relatively low dose progestogen-only therapy. This therapy also has the potential for offering longer-term protection than prior therapies."
The therapy was shown to halt bleeding rapidly while appropriate testing could identify the underlying causes of the excessive bleeding. As such, Dr. Nelson said the therapy provides a "temporary bridge to long-term targeted therapies." She also said the regimen had "good compliance, few side effects and high patient satisfaction." In addition, she said it was an attractive treatment option for women with contraindications to estrogen, those who need more prolonged therapy and those who may have difficulty with daily pill administration.
About LA BioMed
Founded in 1952, LA BioMed is one of the country's leading nonprofit independent biomedical research institutes. It has approximately 100 principal researchers conducting studies into improved treatments and cures for cancer, inherited diseases, infectious diseases, illnesses caused by environmental factors and more. It also educates young scientists and provides community services, including prenatal counseling and childhood nutrition programs. LA BioMed is academically affiliated with the David Geffen School of Medicine at UCLA and located on the campus of Harbor-UCLA Medical Center.